医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aphios Granted Chinese Patent for Novel Bryoid to Treat Alzheimer’s Disease

2021年11月10日 PM10:00
このエントリーをはてなブックマークに追加


 

WOBURN, Mass.

Aphios Corporation today announced that it has been granted Chinese Patent No. 201811111996.8 by China National Intellectual Property Administration on October 26, 2021. The patent entitled, “Bryoid Compositions, Methods of Making and Use Thereof,” covers novel composition of matter of the novel Bryoid, Bryostatin-23 and use for the treatment of Alzheimer’s disease and other neurodegenerative diseases, virus latency diseases such as HIV and Herpes, cancers and glaucoma.

According to Dr. Trevor P. Castor, President and CEO, Aphios Corporation: “This novel Bryoid, Bryostatin-23, is a highly potent nanomolar activator of α-secretase activity in neuroblastoma cell models, being more effective than the canonical Bryostatin-1 at increasing activity of all protein kinase C (PKC) isoforms, particularly the novel PKC isoforms, delta and epsilon. It thus has a higher therapeutic efficacy than Bryostatin-1.”

About Aphios Corporation: Aphios Corporation (www.aphios.com) is a green biotechnology company developing enabling technology platforms for improving drug discovery, manufacturing, delivery and safety, and enhanced natural therapeutics for health maintenance and disease prevention, and treatment of Alzheimer’s disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005572/en/

CONTACT

Trevor P. Castor, Ph.D., CEO

(001) 781-858-7520

tcastor@aphios.com

同じカテゴリーの記事 

  • Poxel to Report Its 2023 Annual Results by the End of April 2024
  • Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft
  • 大手CDMOのPCIファーマ・サービシズが初の包括ESG報告書を発表
  • Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
  • 领先的合同开发和制造组织PCI Pharma Services发布首份综合ESG报告